The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
- 31 July 2010
- journal article
- Published by Elsevier BV in Health Policy
- Vol. 96 (2), 170-177
- https://doi.org/10.1016/j.healthpol.2010.01.014
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing historiesBMJ, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Treatment of postmenopausal osteoporosisThe Lancet, 2002
- A review of the literature on the economics of noncompliance. Room for methodological improvementHealth Policy, 2002
- The impact of non‐compliance on the cost‐effectiveness of pharmaceuticals: a review of the literatureHealth Economics, 2001
- Effect of Risedronate on the Risk of Hip Fracture in Elderly WomenNew England Journal of Medicine, 2001
- Accounting for Noncompliance in Pharmacoeconomic EvaluationsPharmacoEconomics, 2001
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJama-Journal Of The American Medical Association, 1998
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996